Subscribe to RSS
DOI: 10.4103/ijmpo.ijmpo_104_17
Reversible Hypopigmentation with Pazopanib
Financial support and sponsorship Nil.
Abstract
Tablet Pazopanib known to cause Hypo pigmentation and Hyperpigmentation as per various literature reports. We report here a case of reversible hypopigmentation with Pazopanib in a patient treated for spindle cell sarcoma. Patient did not have any clinical symptoms except for cosmetic significance.
Publication History
Article published online:
17 June 2021
© 2018. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009; 15: 4220-7
- 2 Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF. et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-80
- 3 Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-8
- 4 Sideras K, Menefee ME, Burton JK, Erlichman C, Bible KC, Ivy SP. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. J Clin Oncol 2010; 28: e312-3
- 5 Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010; 11: 962-72
- 6 de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J. et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 2013; 31: 751-9
- 7 Teresa M, González JV, Tlahuel JL, Guerra EC. Hypopigmentation of the Skin and Hair Associated with Targeted Therapies. Journal of Cancerology 2014; 1: 67-72
- 8 Moss KG, Toner GC, Cherrington JM, Mendel DB, Laird AD. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 2003; 307: 476-80
- 9 Elhalawani H, Heiba M, Abdel-Rahman O. Risk of distinctive hair changes associated with pazopanib in patients with renal cell carcinoma (RCC) versus patients without RCC: A comparative systematic review and meta-analysis. Clin Genitourin Cancer 2017; 15: e325-35
- 10 Sternberg CN, Hawkins RE, Wagstaff J, Salman P, Mardiak J, Barrios CH. et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update. Eur J Cancer 2013; 49: 1287-96
- 11 GlaxoSmithKline. An open-label, multicentre, randomised phase II study of pazopanib in combination with pemetrexed in first-line treatment of subjects with predominantly non-squamous cell stage IIIB wet/IV non-small cell lung cancer. Bethesda, MD: National Library of Medicine (US); 2000. Available from: https://www.clinicaltrials.gov/ct2/show/NCT 00871403?term¼NCT00871403 and rank¼1.NLM Identifier:NCT00871403. [Last accessed on 2015 Jul 29].
- 12 Johnston SR, Gómez H, Stemmer SM, Richie M, Durante M, Pandite L. et al. A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 2013; 137: 755-66